These studies highlighted the close association between RNF213 and systemic vascular inflammation, which is consistent with a clinical report that plasma samples from patients with moyamoya disease showed elevated serum levels of matrix metalloproteinases 9, monocyte chemoattractant protein-1, proinflammatory interleukins, and vascular endothelial growth factor [34]. This evidence concerns the gene RNF213 and Moyamoya disease.